Inactive Instrument

Galapagos NV Euronext Bruxelles

Equities

GLPG

BE0003818359

Biotechnology & Medical Research

GALAPAGOS : receives €2.7 million IWT grant for antibacterial research

January 10, 2013 at 02:09 pm IST

MarketScreener.com By

Regulated information 10 January 2013

Galapagos receives €2.7 million IWT grant for antibacterial research Mechelen, Belgium; 10 January 2013 - Galapagos NV (Euronext: GLPG) announced today that is has been awarded a €2.7 million grant from the Flemish agency for Innovation by Science and Technology (IWT) to discover new antibiotic treatments.

A number of bacteria have become resistant to existing antibiotics, posing a pressing healthcare problem. In November 2012, Galapagos announced the selection of a candidate drug targeting DNA pol III

Latest news about Galapagos NV

Frontier Medicines Corporation announced that it has received $99.999997 million in funding from a group of investors	25/06	CI
Galapagos Plans to Present 'Encouraging' Results for GLPG5101 in Non-Hodgkin Lymphoma	15/06	MT
Galapagos NV Presents Encouraging New Data for CD19 CAR-T Candidate GLPG5101 in Non-Hodgkin Lymphoma at EHA 2024	15/06	CI
Galapagos, Adaptimmune to Jointly Develop Head, Neck Cancer Treatment	31/05	MT
Galapagos, Adaptimmune Therapeutics Team Up to Evaluate Head and Neck Cancer Drug	31/05	MT
Galapagos and Adaptimmune Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-Cell Therapy Candidate, uza-cel	31/05	CI
Galapagos Partners with Blood Centers of America to Decentralize CAR-T Cell Therapy Manufacture	16/05	MT
Galapagos and Blood Centers of America Announce Strategic Collaboration to Accelerate Galapagos? Decentralized Car-T Manufacturing Network in the U.S	16/05	CI
Transcript : Galapagos NV, Q1 2024 Earnings Call, May 03, 2024	03/05
Galapagos NV Reports Earnings Results for the First Quarter Ended March 31, 2024	03/05	CI
Galapagos Showcases Innovative Approach in Hematological Cancer Care with Clinical and Translational Data Presentations at EBMT Congress 2024	08/04	CI
Galapagos Continues to be 'Value Trap' With Unclear Growth Path, BofA Says	28/03	MT
BofA Securities Downgrades Galapagos to Underperform From Neutral, Says 'Stock Remains a Value Trap'; Adjusts Price Target to $31 From $41	28/03	MT
Galapagos NV Announces Board Changes	27/03	CI
Galapagos to Seek Acquisitions	23/02	CI
Transcript : Galapagos NV, 2023 Earnings Call, Feb 23, 2024	23/02
Frontier Medicines Corporation announced that it has received $80.000001 million in its first tranche from Deerfield Management Company, L.P. Series C, DROIA nv, Galapagos NV, DCVC, MPM Asset Management, L.L.C., RA Capital Management, L.P. and other investors	22/02	CI
Galapagos NV Reports Earnings Results for the Full Year Ended December 31, 2023	22/02	CI
Galapagos NV to Present New Preliminary Translational Data at EBMT-EHA Annual Meeting 2024	16/02	CI
Galapagos Completes Sale of Jyseleca Business to Alfasigma	01/02	MT
Frontier Medicines Corporation announced that it expects to receive $99.999997 million in funding	31/01	CI
Alfasigma S.p.A. completed the acquisition of Filgotinib business from Galapagos NV.	31/01	CI
Galapagos NV Enters into Strategic Collaboration Agreement with Thermo Fisher Scientific, Inc. to Further Expand Its Decentralized CAR-T Manufacturing Network in the U.S	05/01	CI
Galapagos Partners with Thermo Fisher for Manufacturing in US	05/01	MT
Galapagos, Thermo Fisher Scientific to Establish Decentralized CAR-T Manufacturing Network	05/01	MT

Chart Galapagos NV

Duration

Period

More charts

Company Profile

Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. The company is committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan.

Sector

Biotechnology & Medical Research

Calendar

01/08/2024 - Q2 2024 Earnings Release

Related indices

BEL-20

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+24.74%	47.54B
IQVIA HOLDINGS INC.	-0.47%	41.96B
LONZA GROUP AG	+43.96%	41.55B
ALNYLAM PHARMACEUTICALS, INC.	+25.40%	30.36B
ICON PUBLIC LIMITED COMPANY	+17.96%	27.61B
CELLTRION, INC.	-4.47%	28.7B
UNITED THERAPEUTICS CORPORATION	+50.73%	14.7B
MEDPACE HOLDINGS, INC.	+42.56%	13.51B
BIO-TECHNE CORPORATION	+1.46%	12.34B

Other Biotechnology & Medical Research